Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy

Journal of Clinical Psychiatry

Volumn 58, Issue 4, 1997, Pages 137-145

  Bodkin, J Alexander ^a   Lasser, Robert A ^b   Wines Jr , James D ^b   Gardner, David M ^b   Baldessarini, Ross J ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLONAZEPAM; ESTAZOLAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; PROPRANOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; VALPROATE SEMISODIUM;

ADULT; AFFECTIVE NEUROSIS; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INSOMNIA; MALE; MANIC DEPRESSIVE PSYCHOSIS; MUSCLE WEAKNESS; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; TREMOR;

EID: 0030982240     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0401     Document Type: Article

References (41)

1. Baldessatini RJ. Current status of antidepressants: clinical pharmacology and therapy [Festschrift]. J Clin Psychiatry 1989;50:117-126
2. Burke MJ, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1053-1065
3. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Harden W, Rudin W, Molinoff PB, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:431-459
4. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
5. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
6. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
7. Griest JH, Jefferson JW, Koback KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
8. Sheehan DV, Davidson J, Manshreck T. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobia. J Clin Psychopharmacol 1983;3:28-31
9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-1020
10. Barrickman L, Perry P, Allen A, et al. Bupropion vs methylphenidate in the treatment of attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-657
11. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit-hyperactivity disorder across the life-cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432
12. Cole JO, Friedman LM, Gold R, et al. Efficacy of bupropion in depressed fluoxetine nonresponders. Presented at the 32nd annual meeting of the New Clinical Drug Evaluation Unit Annual Meeting; May 26-29, 1992; Key Biscayne, Fla
13. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
14. Labatte LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. Ann Clin Psychiatry 1994;6:13-15
15. Rothschild AJ. SSRI-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;15:1514-1516
16. Preskom SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21
17. Novac A. Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. J Clin Psychiatry 1992;53:67
18. Boyer WF, Feighner J. The combined use of fluoxetine and bupropion. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 27, 1993; San Francisco, Calif. Abstract NR746:247
19. Marshall RD, Johannet CM, Collins PY, et al. Bupropion and sertraline combination treatment in refractory depression. Journal of Psychopharmacology 1995;9:284-286
20. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996;16:80-81
21. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994;309: 249-253
22. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50:256-261
23. Popli A, Baldessarini RJ, Cole JO. Interactions of serotonin-reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1994;51: 666-667
24. Preskorn SH. Drug-drug interactions [letter with reply]. J Clin Psychiatry 1996;57:223-225
25. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serotonin reuptake inhibitors alter metabolism of clozapine. Am J Psychiatry 1996; 153:820-822
26. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991; 52:329-335
27. Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990; 10:343-345
28. Beasley CM, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52:294-299
29. Keck PE Jr, McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992;53:127-129
30. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. American Journal of Therapeutics 1996;3:492-496
31. Conn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53(2, suppl):52-56
32. Peck AW, Hamilton M. Psychopharmacology of bupropion in normal volunteers. J Clin Psychiatry 1983;44(5, sec 2):202-205
33. Sabalesky DA. Fluoxetine in adults with residual attention deficit disorder and hypersomnolence. J Neuropsychiatry Clin Neurosci 1990;2:463-464
34. Jacobsen JM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-122
35. Goddard AW, Woods SW, Sholomskas DE, et al. Effects of fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1991; 48:119-133
36. Hollander E, DeCaria C, Gully R, et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine response to m-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1993; 36:1-18
37. Kahn RS, Kalus O, Wetzler S, et al. The role of serotonin in the regulation of anxiety. In: Brown S, van Praag HM, eds. The Role of Serotonin in Psychiatric Disorders. New York, NY: Brunner/Mazel; 1991:129-160
38. Van Putten T, Shaffer I. Delirium associated with bupropion [letter]. J Clin Psychopharmacol 1990;10:234
39. Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. J Clin Psychopharmacol 1991;11:327-328
40. Ciraulo DA, Shader RJ. Fluoxetine drug-drug interactions, II. J Clin Psychopharmacol 1990;10:213-217
41. Preskorn SH. Should bupropion dosage be adjusted based on therapeutic drug monitoring? Psychopharmacol Bull 1991;27:637-643